Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Topical Drug Delivery: Needs and Strategies


Affiliations
1 Denison Pharmaceuticals, LLC, 1 Powder Hill Road, Lincoln, RI 02865, United States
     

   Subscribe/Renew Journal


This article intends to provide an overview of the delivery of drugs topically (considering mainly semisolid dosage forms). Different topical drug delivery systems have been reviewed considering their advantages and disadvantages and modes of action. Several formulation aspects i.e. things to consider during their formulation, have also been discussed. Some novel drug delivery systems (e.g. dendrimers, cyclodextrin-stabilized micromeulsions, neosomes, emugels, ethosomes) have also been reviewed capturing the unique opportunities for delivering drugs topically
Subscription Login to verify subscription
User
Notifications
Font Size


  • R. K. Chang, A. Raw, R. Lionberger, and L. Yu, The AAPS J. 15, 41 (2012).
  • K. S. Paudel, M. Milewski, C. L. Swadley, N. K. Brogden, P. Ghosh, and A. L. Stinchcomb, Ther Deliv., 1, 109 (2010).
  • M. Pradhan, D. Singh, and M. R. Singh, J. Control. Release,170, 380 (2013).
  • C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, Adv. Drug Deliv. Rev., 46 (1-3), 3 (2001).
  • A. Fick, A. Poggendorff’s, 94, 59 (1855) and (in English) Phil. Mag., S4, 10, 3 (1855).
  • J. Hadgraft and R. H. Guy, ‘Feasibility assessment in topical and transdermal delivery: Mathematical models and in vitro studies’ in Transdermal drug delivery. 2nd edition. Eds. R. Guy, and J. Hadgraft, Marcel Dekker, New York. 1 (2003).
  • T. J. Higuchi, J. Pharm Sci., 50, 874 (1961).
  • P. J. Sinko, Diffusion. In Martin's physical pharmacy and pharmaceutical sciences. 5th edition, Ed: P. J. Sinko,
  • Lippincott Williams & Wilkins, 301 (2006).
  • http://www.fda.gov/downloads/Drugs/Guidances/UCM070930.pdf
  • R. K. Chang, A. Raw, R. Lionberger, and L. Yu, The AAPS J. , 15, 675 (2013).
  • World Pharma Network, July 2007, pp 31–33.
  • L. Lachman and H. A. Lieberman, The Theory and Practice of Industrial Pharmacy 3rd Edition, Varghese Publishing house, 536 (1991).
  • R. P. Selvam, A. K. Singh, and T. Sivakumar, Int. J. Phar. Biomed Res., 1, 1, (2010).
  • L. Buhse, R. Kolinski, B. Westenberger, A. Wokovich, J. Spencer, C. W. Chen, S. Turujman, M. Gautam-Basak, G.J. Kang, A. Kibbe, B. Heintzelman, and E. Wolfgang, Int. J. Pharm., 295, 101 (2005).
  • D. Osborne, Pharm Tech., 10, 68 (2008).
  • L. Gan, J. Wang, M. Jiang, H. Bartlett, D. Ouyang, F. Eperjesi, J. Liu and Y. Gan, Drug Discovery Today, 18, No
  • -/6 (2013).
  • Z. Vanic and N. S. Basnet, Eur. J. Pharm. Sci. 50, 29 (2013).
  • S. Heuschkel, A. Goebel and R. H. H. Neubert, J. Pharmaceuticals Sci., 97, 603 (2008).
  • A. Kogan and N. Garti, Adv. Colloid Sci., 123, 369 (2006).
  • M. Kreilgaard, Advanced Drug Delivery Reviews. 54 Suppl.1, S7 (2002).
  • S. Gupta and S. P. Moulik, J. Pharm. Sci., 97, 22 (2008).
  • E. Touitou, N. Dayan, L. Bergelson, B. Godin, and M. Eliaz, J. Control. Release, 65, 403 (2000).
  • M. M. Elsayed, O. Y. Abdallah, V. F. Naggar, and N. M. Khalafallah. Int. J. Pharm., 332, 1 (2007).
  • R. W. Lee, D. B. Shenoy, and R. Sheel, ‘Micellar Nanoparticles: Applications for Topical and Passive Transdermal Drug
  • Delivery”. In Handbook of Non-Invasive Drug Delivery Systems, Chapter 2, Ed. V. S. Kulkarni Elsevier Inc. (2010).
  • P. Desai, R. R. Patlolla, and M. Singh, Mol. Membr. Biol. 27,247 (2010).
  • J. Y. Fang, C. L. Fang, C. H. Liu, and Y. H. Su, Eur. J. Pharm. Biopharm., 70, 633 (2008).
  • P. Nahak, G. Karmakar, B. Roy, P. Guha, M. Sapkota, S. Koirala, C. H. Chang and A. K. Panda, RSC Adv., 5, 26061
  • (2015).
  • M. R. Mozafari, Cell. Mol. Biol. Lett. 10, 711 (2005).
  • S. Narasimha Murthy and H. N. Shivakumar, ‘Topical and Transdermal Drug Delivery’. In Handbook of Non-Invasive
  • Drug Delivery Systems, Chapter 1, Ed. V. S. Kulkarni Elsevier Inc. (2009)
  • S. Pappinen and Aurtti, ‘Microemulsions in Topical Drug Delivery’. In Percutaneous Penetration Enhancers, Eds. E. W.
  • Smith and H. I. Maibach, 2nd Edn, CRC Press, Chapter 9, 113 (2005)
  • J. Zhang, P. X. Ma, Adv. Drug Deliv. Rev., 65, 1215 (2013).
  • P. R. Majhi and M. W. Trumbore, United States Patent 20130251644 A1.
  • P. R. Majhi and M. W. Trumbore, United States Patent 20130253015 A1.
  • M. W. Trumbore, P. R Majhi, and D. Shah, United States Patent United States 9, 018, 236.
  • S. Mignanai, S. E. Kazzouli, M. Bousmina and J. P. Majoral, Adv. Drug Deliv. Rev., 65, 1316 (2013).
  • M. Sun, A. Fan, Z. Wang, Y. Zhao, Soft Matter, 8, 4301(2012).
  • Ajazuddin, A. Alexander, A. Khichariya, S. Gupta, R. J. Patel, T. K. Giri, and D. K. Tripathi, J. Control. Release,? 171,
  • (2013).

Abstract Views: 344

PDF Views: 0




  • Topical Drug Delivery: Needs and Strategies

Abstract Views: 344  |  PDF Views: 0

Authors

Pinaki R. Majhi
Denison Pharmaceuticals, LLC, 1 Powder Hill Road, Lincoln, RI 02865, United States

Abstract


This article intends to provide an overview of the delivery of drugs topically (considering mainly semisolid dosage forms). Different topical drug delivery systems have been reviewed considering their advantages and disadvantages and modes of action. Several formulation aspects i.e. things to consider during their formulation, have also been discussed. Some novel drug delivery systems (e.g. dendrimers, cyclodextrin-stabilized micromeulsions, neosomes, emugels, ethosomes) have also been reviewed capturing the unique opportunities for delivering drugs topically

References





DOI: https://doi.org/10.17834/ijsstissst.v31i1-2.79930